SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of “Moderate Buy” from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $11.8750.

Several equities research analysts recently commented on the company. Jefferies Financial Group assumed coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price on the stock. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Finally, Citigroup assumed coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price on the stock.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABS opened at $4.00 on Monday. The company has a market cap of $305.84 million, a P/E ratio of -1.90 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics has a one year low of $1.67 and a one year high of $6.60. The business’s 50-day simple moving average is $3.70 and its 200 day simple moving average is $3.85.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, sell-side analysts forecast that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. acquired a new stake in SAB Biotherapeutics during the 1st quarter valued at approximately $29,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $34,000. ADAR1 Capital Management LLC grew its position in shares of SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after acquiring an additional 11,344 shares in the last quarter. State Street Corp acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $49,000. Finally, Fifth Lane Capital LP acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.